Investment Rating - The report maintains an "Accumulate" rating for Yum China (9987.HK) [1] Core Insights - In Q4 2025, the company achieved revenue of $2.823 billion, a 9% increase year-over-year, with operating profit rising by 25% to $187 million, and net profit attributable to shareholders increasing by 24% to $140 million. For the entire year, revenue reached $11.797 billion, up 4%, with operating profit at $1.290 billion (+11%) and net profit at $929 million (+2%) [2] - The company returned $539 million to shareholders in Q4 2025, totaling $1.5 billion for the year, with plans to maintain this level of shareholder return in 2026 [2] Summary by Sections Same-Store Sales and Store Expansion - The company reported same-store sales growth for three consecutive quarters, with system sales and same-store sales increasing by 7% and 3% year-over-year in Q4 2025, respectively. A total of 587 new stores were added in the quarter, bringing the annual total to 1,706 new stores, with 31% being franchise stores [3] - By brand, KFC saw system sales and same-store sales growth of 8% and 3% in Q4 2025, respectively, with 357 new stores opened. For the year, KFC's system sales and same-store sales grew by 5% and 1%, respectively, with 1,349 new stores [3] - Pizza Hut experienced system sales and same-store sales growth of 6% and 1% in Q4 2025, with 146 new stores opened. For the year, system sales and same-store sales grew by 4% and 1%, respectively, with 444 new stores [3] New Store Formats and Innovations - The company is expanding its product offerings and store formats to reach a broader customer base. K Coffee and KPRO have shown rapid growth, with K Coffee in 2,200 stores and KPRO expected to double to over 400 stores in 2026. Pizza Hut has successfully entered around 100 new towns with the WOW store model [4] - The company has introduced the "Twin Stars" model, placing KFC and Pizza Hut stores adjacent to each other to penetrate lower-tier markets at a lower cost, with approximately 40 pairs of "Twin Stars" stores opened and plans for accelerated expansion in 2026 [4] Cost Management and Profitability - In Q4 2025, the company's operating profit margin and restaurant profit margin improved to 6.6% and 13.0%, respectively, benefiting from operational efficiencies and favorable raw material prices. KFC's operating profit margin was 10.5%, while Pizza Hut's was 3.7% [5] - The company reported a decrease in the proportion of food and packaging costs by 0.3 percentage points year-over-year, while labor costs increased by 1.2 percentage points. Rental and other expenses decreased by 1.6 percentage points, with delivery sales accounting for 53% of total sales, an increase of 11 percentage points [5] Financial Forecast and Valuation - The report adjusts previous profit forecasts and introduces projections for 2028, estimating revenues of $12.522 billion, $13.264 billion, and $13.983 billion for 2026, 2027, and 2028, respectively. Net profits are projected at $1.015 billion, $1.127 billion, and $1.228 billion for the same years [6] - The latest stock price corresponds to a price-to-earnings ratio of 19, 17, and 16 times for 2026, 2027, and 2028, respectively, maintaining the "Accumulate" rating [6]

Investment Rating - The report maintains a "Buy" rating for the company with a target price adjusted to HKD 42.10 [4][7]. Core Insights - The company's product sales revenue is expected to continue growing rapidly, driven by the successful launch of key innovative drugs in the oncology and liver disease sectors [1][3]. - Increased promotional efforts are anticipated, particularly with the upcoming launch of the drug Amivantamab in the UK, which may lead to higher sales expenses [2]. - Long-term revenue from licensing agreements is expected to increase, particularly from a deal with Glenmark Specialty for the commercialization of Amivantamab in various regions [3]. Financial Summary - Revenue projections for the company are as follows: - 2023: RMB 10,104 million - 2024: RMB 12,261 million (growth rate of 21.3%) - 2025E: RMB 15,426 million (growth rate of 25.8%) - 2026E: RMB 15,600 million (growth rate of 1.1%) - 2027E: RMB 17,644 million (growth rate of 13.1%) [6][12] - Shareholder net profit estimates are: - 2023: RMB 3,278 million - 2024: RMB 4,372 million (growth rate of 33.4%) - 2025E: RMB 5,434 million (growth rate of 24.3%) - 2026E: RMB 4,739 million (decline of 12.8%) - 2027E: RMB 5,828 million (growth rate of 23.0%) [6][12] - The company’s earnings per share (EPS) projections are: - 2023: RMB 0.55 - 2024: RMB 0.74 - 2025E: RMB 0.92 - 2026E: RMB 0.79 - 2027E: RMB 0.98 [6][12] Target Price and Valuation - The target price has been adjusted to HKD 42.10 based on a discounted cash flow (DCF) model, reflecting a potential upside from the current price of HKD 36.62 [4][7].

[Table_Page] 公司深度研究|汽车与汽车零部件 证券研究报告 | [Table_Title] 【广发汽车&电新&海外】小鹏汽 | | --- | | 车-W(09868.HK)/小鹏汽车(XPEV) | | 十载磨砺成体系，多维增长引擎或将驱动 | | 价值重估 | [Table_Summary] 核心观点： | EBITDA | -9,307 | -4,523 | 185 | 3,590 | 6,812 | | --- | --- | --- | --- | --- | --- | | 归母净利润 | -10,431 | -5,761 | -1,647 | 2,045 | 4,739 | | 增长率（ % ） | - | - | - | - | 131.7% | | EPS（元/股） | -5.53 | -3.03 | -0.86 | 1.07 | 2.48 | | 市盈率（P/E） | - | - | - | 56.0 | 24.2 | | ROE（%） | -28.7% | -18.4% | -5.6% | 6.5% | 13.1% | | EV/EBITDA | - | - | 500.8 ...

中集安瑞科(03899):料印尼项目最多贡献7,000万人民币利润,予"增持"评级 该行预期有关进展将进一步提振市场对公司的情绪，因项目反映公司新业务举措的海外扩张正从愿景迈向 实际执行阶段。同时，该项目是公司第5个焦炉煤气项目，增强了其长远持续增长的能见度，缓解了投资者先 前对于净利润增长放缓的忧虑，因公司的三项新业务均为项目制(project-based)。 摩根大通 摩根大通发布研报称，中集安瑞科(11.71,-0.33,-2.74%)(03899)公布其在印尼的首个海外焦炉煤气项 目。该行估计，若项目达至最高产能，可为公司贡献约7,000万元人民币的利润，约占2025财年预测净利润的 6%;现予中集安瑞科"增持"评级，目标价12港元。 ...

Investment Rating - The report maintains a "Buy" rating for China Aircraft Leasing Group (02588) [1] Core Insights - China Aircraft Leasing is benefiting from a renewed acceleration in asset growth and is entering a new cycle of rising Return on Equity (ROE), with an expected ROE of 11.7% in 2026 and 12.7% in 2027, up from 10.9% in 2025 [1] - The target price for the company has been raised from HKD 86.5 to HKD 96.9, indicating potential for re-rating as ROE improves [1] - The estimated profit for the previous year is approximately USD 720 million, with capital expenditures aligning with the forecast of USD 4 billion [1] Financial Projections - Leasing business revenue is projected to accelerate from a 1% growth in the first half of the previous year to a forecasted 5.5% growth in the second half [1] - The expected annual dividend is USD 0.36, with a payout ratio of 35%, although there is potential for a more generous dividend policy due to the company's improved capital structure [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the stock's performance in the coming months [6]. Core Insights - The company, Sheng Bella, is expected to achieve a revenue of no less than 1.035 billion yuan in 2025, representing a year-on-year growth of at least 30%. The adjusted net profit is projected to be no less than 120 million yuan, reflecting a significant increase of 183% [1]. - The company is actively expanding its store network, with a total of 113 stores as of the first half of 2025, an increase of 36 stores compared to the end of 2024. This expansion is expected to enhance customer recognition and improve data richness for AI applications [2]. - The management's confidence in the company's growth is demonstrated through a share incentive plan and stock purchases by the chairman, indicating a commitment to long-term value creation [3]. Financial Projections - Revenue projections for 2025-2027 are as follows: 1.0365 billion yuan in 2025, 1.302 billion yuan in 2026, and 1.601 billion yuan in 2027, with corresponding adjusted net profits of 119 million yuan, 232 million yuan, and 288 million yuan respectively [4][5]. - The company is expected to achieve a price-to-earnings (P/E) ratio of 22.26 in 2025, decreasing to 9.23 by 2027, indicating improving profitability over time [5].

2026 年 02 月 06 日 | C0062@capital.com.tw | | | --- | --- | | 王睿哲 目标价(港元) | 26.5 | 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/2/5) | | 20.52 | | 恒生指数(2026/2/5) | | 26,885.24 | | 股价 12 个月高/低 | | 28.80/12.61 | | 总发行股数(百万) | | 2,670.43 | | H 股数(百万) | | 540.97 | | H 市值(亿港元) | | 111.01 | | | | 上海复星高科技 | | 主要股东 | | (集团)有限公司 | | | | (36.15%) | | 每股净值(元) | | 18.06 | | 股价/帐面净值 | | 1.14 | | | 一个月 | 三个月 一年 | | 股价涨跌(%) | -0.97% | -9.92% 62.68% | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/12/10 | 21 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][11][6]. Core Insights - The company is a leader in domestic surgical robotics, driving advancements in surgical procedures through continuous technological innovation. With rapid growth in global clinical surgical volumes, the company is experiencing significant revenue growth alongside increasing domestic sales and commercialization in overseas markets [2][11]. Summary by Sections 1. Domestic Surgical Robotics Leader - The company was founded in May 2017 in Shenzhen and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots. It has developed a "three-in-one" surgical solution combining multi-port, single-port, and remote systems [15][11]. - The company has achieved the highest sales volume among domestic manufacturers in 2024, with 20 units of its multi-port surgical robot sold in China, covering over 220 hospitals across 30 provinces [11][29]. - Revenue is projected to grow from RMB 0.48 billion in 2023 to RMB 1.6 billion in 2024, driven by increased sales and market acceptance of its products [29][30]. 2. Clinical Advantages of Surgical Robots - Surgical robots provide significant clinical benefits, including high precision, stability, and repeatability, which traditional laparoscopic surgeries struggle to achieve. This technology is transforming the landscape of minimally invasive surgeries [38][39]. 3. International Expansion and Sales Growth - The company has successfully entered overseas markets, securing five orders in 2024 and establishing a distribution network across five continents. By the end of 2025, it had signed global sales agreements for 118 units, with 72 units designated for international markets [11][29]. - The company’s internationalization efforts have marked a transition from initial market testing to large-scale expansion [11][29]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are RMB 4.32 billion, RMB 8.11 billion, and RMB 12.36 billion, respectively, reflecting substantial growth rates of 170% and 88% in the following years [4][11]. - The company is expected to turn profitable by 2026, with net profit projected to reach RMB 167 million by 2027, following a loss of RMB 219 million in 2024 [4][11]. 5. Management Team and R&D Strength - The management team, led by experienced founders, has built a proprietary technology platform supported by a multidisciplinary R&D team of 265 members. The company holds the highest number of patents in the Chinese surgical robotics sector [20][25]. - The company has established a comprehensive technology platform based on seven proprietary core technology modules, enhancing its competitive edge in the market [26][27].

Investment Rating - The investment rating for the company is "Buy" [4][9]. Core Insights - The company has launched the visionJet G3, which features significant upgrades in consumer orientation, including a fully upgraded avionics system, enhanced cabin comfort, and improved performance metrics such as maximum flight speed and payload capacity [1][4]. - The target customer base is high-net-worth individuals rather than professional pilots, focusing on smart and safe performance upgrades to address pain points during flights, which is expected to enhance customer acquisition and market penetration [1]. - The company is expanding its production capacity and improving its delivery structure, which is anticipated to lead to better order fulfillment and increased revenue from new product lines [1][4]. Financial Projections - Revenue is projected to grow from $1,068 million in 2023 to $1,902 million in 2027, with a compound annual growth rate (CAGR) of approximately 17.1% [3][8]. - Net profit is expected to increase from $91 million in 2023 to $237 million in 2027, reflecting a CAGR of about 22.8% [3][8]. - Earnings per share (EPS) is forecasted to rise from $0.59 in 2023 to $0.65 in 2027, with a decreasing price-to-earnings (P/E) ratio from 32.4 in 2023 to 12.4 in 2027, indicating potential valuation recovery [3][8].

证券研究报告·海外公司点评·旅游及消闲设施(HS) 百胜中国（09987.HK） 百胜中国 2025Q4 及全年业绩公告点评：质 地稳健的高股息龙头，维持推荐 买入（维持） | [Table_EPS] 盈利预测与估值 | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万美元） | 11,303 | 11,797 | 12,686 | 13,426 | 14,262 | | 同比(%) | 2.96 | 4.37 | 7.54 | 5.83 | 6.23 | | 归母净利润（百万美元） | 911.00 | 929.00 | 1,042.71 | 1,143.75 | 1,262.86 | | 同比(%) | 10.16 | 1.98 | 12.24 | 9.69 | 10.41 | | EPS-最新摊薄（美元/股） | 2.57 | 2.62 | 2.94 | 3.23 | 3.56 | | P/E（现价&最新摊薄） | 22.10 | 21.67 | 19.31 | 17.61 | ...